海思科医药集团股份有限公司：5%以上股东一致行动人减持股份触及1%整数倍

公告要点概述

• 减持主体：公司5%以上股东之一致行动人杨飞女士于2026年3月17日至3月19日期间，通过集中竞价方式减持公司股份2,169,400股，约占公司总股本的0.19%。
• 减持计划与进度：本次减持为公司于2026年2月3日已披露的减持计划中的一部分。减持计划规定，杨飞女士计划在三个月内减持不超过8,000,000股（占总股本0.71%），目前已减持2,169,400股（占总股本0.19%），计划尚在履行中。
• 后续持股变动：本次减持后，杨飞女士及其一致行动人范秀莲女士合计持有公司股份由259,757,886股降至257,588,486股，合计持股比例由23.19%降至23.00%，变动比例触及1%整数倍。
• 不会导致控制权变更：本次权益变动不会导致公司实际控制权发生变更，也不会对公司治理结构及持续经营产生重大影响。
• 合规披露：本次减持行为已提前披露，且不存在违反相关法律法规及交易所业务规则的情形。

详细内容解读

2026年3月19日，海思科医药集团股份有限公司发布公告称，公司5%以上股东之一致行动人杨飞女士因个人资金需求，于2026年3月17日至3月19日通过深圳证券交易所集中竞价方式减持公司股份2,169,400股。

减持完成后，杨飞女士持有公司股份由42,442,286股减少至40,272,886股，持股比例由3.79%降至3.60%。一致行动人范秀莲女士本次未发生权益变动，仍持有217,315,600股（占总股本19.40%）。杨飞、范秀莲合计持股由23.19%降至23.00%，持股比例变动达到1%整数倍，对外进行了信息披露。

值得注意的是，此次减持行为属于公司2026年2月3日提前披露的减持计划内容。该计划显示，杨飞女士计划在公告披露之日后十五个交易日内的三个月内，通过大宗交易或集中竞价方式减持不超过8,000,000股。截至公告披露日已减持2,169,400股，后续减持仍有空间。

对投资者的影响及注意事项

• 可能影响股价：大股东减持通常会被市场解读为对公司未来股价的信心减弱，可能对股价带来压力。尤其是本次减持触及1%的整数倍，属于较为敏感的持股比例变动。
• 后续减持计划存在不确定性：根据已披露计划，杨飞女士在未来三个月内仍有可能继续减持，投资者应持续关注相关公告。
• 公司治理结构稳定：本次权益变动不会导致公司控制权变更，对公司治理结构及持续经营无重大影响，基本面保持稳定。
• 合规性：本次减持严格按照相关法规合规披露，未出现违规情形。

结论

对于海思科医药集团股份有限公司的投资者而言，本次公告虽然不会影响公司控制权及治理结构，但5%以上重要股东的持续减持行为极有可能引发市场关注和股价波动，需密切关注后续减持进展和相关披露信息。

免责声明： 本文仅作信息披露解读参考，不构成任何投资建议。投资者据此操作，风险自负。请持续关注公司后续公告。

English Translation

Hisun Pharmaceutical Group: 5%+ Shareholder Acting-in-Concert Reduces Shares, Hitting 1% Threshold

Key Points Summary

• Shareholder Reduction: Ms. Yang Fei, an acting-in-concert party holding over 5%, reduced her shares by 2,169,400 (0.19% of total share capital) via block trading on March 17-19, 2026.
• Disclosed Plan and Progress: This was part of a previously announced plan (Feb 3, 2026) allowing Yang Fei to reduce up to 8,000,000 shares (0.71%). So far, 2,169,400 shares have been sold (0.19%).
• Post-reduction Holdings: Yang Fei and acting-in-concert Fan Xiulian together now hold 257,588,486 shares, down from 259,757,886, with their combined shareholding falling from 23.19% to 23.00%, hitting the sensitive 1% threshold.
• No Change in Control: The reduction does not affect the company’s control or governance structure.
• Compliance: The reduction was fully disclosed in advance and is in accordance with all relevant laws and regulations.

Detailed Analysis

On March 19, 2026, Hisun Pharmaceutical Group announced that Ms. Yang Fei, a major shareholder and acting-in-concert party, sold 2,169,400 shares for personal funding needs via block trading between March 17 and March 19, 2026.

After the sale, Ms. Yang Fei’s shareholding dropped from 42,442,286 (3.79%) to 40,272,886 (3.60%). Ms. Fan Xiulian, the acting-in-concert party, did not change her holding, which remains at 217,315,600 shares (19.40%). Combined, their shareholding decreased from 23.19% to 23.00%, crossing the 1% integer threshold—a sensitive signal for the market.

This reduction follows a plan announced on February 3, 2026, which allowed Yang Fei to sell up to 8,000,000 shares within three months. As of this disclosure, 2,169,400 shares have been sold and further reductions are possible.

Investor Implications & Key Issues

• Potential Price Impact: Large shareholder reductions are often viewed as a negative market signal and may put pressure on the share price, especially when hitting key thresholds.
• Ongoing Reduction Risk: Yang Fei may continue to sell up to the plan’s limit, so investors should monitor future disclosures closely.
• Governance Stability: The reduction does not affect control or management continuity.
• Regulatory Compliance: The sale was legal and fully disclosed.

Conclusion

For investors, while the company’s fundamentals and control remain unchanged, ongoing share reductions by a major shareholder could spark further market volatility. Continuous monitoring is advised.

Disclaimer: This article is for information purposes only and does not constitute investment advice. Investors operate at their own risk. Please follow company announcements for the latest updates.

View 海思科 Historical chart here